Key takeaways:

The therapy received five orphan designations from the European Medicines Agency.

MCO-010 previously received orphan drug and fast track designations in Stargardt disease and retinitis pigmentosa.

Editor’s note: This is a developing news story. Please check back soon for updates.

The FDA granted regenerative medicine advanced therapy designation for MCO-010 for the treatment of Stargardt disease, according to a press release from Nanoscope Therapeutics.

MCO-010 previously received orphan drug and fast track designations in Stargardt disease and retinitis pigmentosa.

MCO-010 (sonpiretigene isteparvovec) also received five European Medicines Agency orphan designations that cover non-syndromic and syndromic rod-dominant and cone-dominant dystrophies as well as macular dys

See Full Page